Researchers at Tallaght Hospital have discovered that a ‘ground-breaking’ drug named Rucaparib is effective in the treatment of certain prostate cancers.
In a statement released on Tuesday, it was confirmed that the Dublin-based hospital took part in a clinical trial of the new drug starting in 2017.
The trial focused on patients with prostate cancer which had spread over time, testing how they responded to Rucaparib in place of other more commonly known treatments.
READ MORE: Charlie Bird thanks Bank of Ireland staff for their help after 'crying uncontrollably'
“Medical researchers at Tallaght University Hospital (TUH) have taken part in a ground-breaking Clinical Trial which has discovered that the drug Rucaparib is successful in the treatment of certain prostate cancers. The trial which began in TUH in 2017, was called TRITON 3,” the statement read.
“The purpose of the study was to determine how patients with prostate cancer (which had spread) responded to treatment with the drug Rucaparib versus treatment with other drugs (such as Abiraterone Acetate, Enzalutamide or Docetaxel). The trial only involved men who had either a BRCA or ATM gene mutation”.
It went on to say: “All of the patients who took part in this study also had what is known as castrate-resistant prostate cancer. In short, this means that prostate cancer keeps growing even when the amount of testosterone in the body is reduced to very low levels.
“Over a 5-year period, TUH screened 120 men for this study. Patients were then asked if they would like to participate in this trial. Once consent was given, a blood sample was shipped to Foundation Medicine in the USA.
“Here, the blood was tested for a panel of genes. If the patient sample was positive for certain genes they were contacted and asked if they would like to participate in the trial. They were then randomised to receive the study drug Rucaparib”.
Clinical Professor of Medical Oncology at TUH, Ray Mc Dermott was one of the principal investigators for this Trial and is the National Cancer ControI Programme lead in guideline development for prostate cancer.
Seventeen patients (13 of which were being treated in TUH) had the required genes and met all other eligibility criteria and proceeded to the main trial.
“Patients were reviewed regularly by the Oncology Clinical Trials team in TUH and all scans were reported by Prof William Torreggiani, Consultant Radiologist. The drugs were supplied via the TUH pharmacy department,” researchers confirmed.
“The highly regarded New England Journal of Medicine has just reported that the TRITON 3 Trial demonstrated that progression-free survival was significantly improved when patients with metastatic castration-resistant prostate cancer were treated with Rucaparib versus other medications”.
It also found that Rucaparib provides a potential treatment option for eligible men, with earlier-stage disease.
These results have just been published in San Francisco at a conference organised by the American Society of Clinical Oncology which focused on genitourinary cancers.
READ NEXT:
Irish Tesco shoppers warned popular product may be ‘unsafe’ to eat
Gardai probing alleged knife murder get more time to quiz suspect
Brooke Scullion fined €300 after pet cat 'wrecked' Dublin apartment
Stepdad of missing Amy Fitzpatrick appears in court over alleged assault
David Beckham and son Cruz, 18, hit the pub again as they sink pints in Dublin
Get breaking news to your inbox by signing up to our newsletter
